Gepreda®

Ademetionine belongs to the group of hepatoprotectors. It has a choleretic effect, has detoxifying, regenerating, antioxidant, antifibrosion and neuroprotective properties.

Ademethionine (S-adenosyl-L-methionine) is a naturally occurring amino acid that is present in virtually all tissues and body fluids. The highest concentration of ademethionine was found in the liver and brain. Ademethionine is a derivative of the sulfur–containing amino acid methionine. It plays a key role in the metabolic processes of the body, participates in important biochemical reactions. Participates in the synthesis of phospholipids of cell membranes, neurotransmitters, nucleic acids, proteins, hormones, etc.

Ademetionine is a precursor of cysteine, taurine, glutathione (providing the redox mechanism of cellular detoxification), coenzyme A (involved in the biochemical reactions of the tricarboxylic acid cycle and replenishes the energy potential of the cell).

Increases the content of glutamine in the liver, cysteine and taurine in plasma; reduces the content of methionine in serum, normalizing metabolic reactions in the liver. It is indirectly involved in stimulating the regeneration and proliferation of liver cells, which reduces the risk of fibrosis.

Ademetionine normalizes the synthesis of endogenous phosphatidylcholine in hepatocytes, which increases the fluidity and polarization of membranes. This improves the function of bile acid transport systems associated with hepatocyte membranes and promotes the passage of bile acids into the biliary tract. It is effective in the intracellular variant of cholestasis (violation
synthesis and flow of bile). Ademetionine reduces the toxicity of bile acids in liver cells. In patients with diffuse liver diseases (cirrhosis, hepatitis), ademetionine reduces the severity of skin itching and improves blood biochemical parameters, including the concentration of direct bilirubin, activity of alkaline phosphatase, aminotransferases, etc.
The choleretic and hepatoprotective effect persists for up to 3 months after discontinuation of treatment. Efficacy has been shown in hepatopathies caused by various hepatotoxic drugs. A number of studies have confirmed the effectiveness of ademetionine in the treatment of fatigue in patients with chronic liver diseases.

• Adjunctive therapy for established chronic liver diseases, to improve and maintain its functions
• Increased fatigue with established chronic liver diseases

Overdose with GEPREDA is unlikely.
In case of overdose with GEPREDA®, you should immediately consult a doctor.
Treatment: symptomatic.

Among the most common adverse reactions identified in clinical trials involving more than 2,000 patients were headache, nausea, and diarrhea.
The following are data on adverse reactions observed during clinical trials (n = 1922) and in the post-marketing follow-up period ("spontaneous" reports).
Adverse reactions are distributed by systemic organ classes and frequency of occurrence: very common (≥ 1/10); common (≥ 1/100, but <1/10); infrequent (≥ 1/1000, but <1/100); rare (≥ 1/10000, but <1/1000); very rare (<1/10000); frequency unknown (it is impossible to estimate based on the available data).

• Genetic disorders affecting the methionine cycle and/or causing homocystinuria and/or hyperhomocysteinemia (cystathionine beta synthase deficiency, impaired vitamin B12 metabolism)
• Hypersensitivity to ademetionine and/or to any of the excipients in the preparation
• Under 18 years of age (due to the lack of data on the efficacy and safety of ademethionine in this age population)
• Bipolar disorders

There have been no known interactions with other drugs. If you are using the following or other medications (including over-the-counter medications), consult your doctor before using GEPREDA®. There is a report of excess serotonin syndrome in a patient taking ademetionine and clomipramine. It is believed that such an interaction is possible, and ademetionine should be used with caution together with selective serotonin reuptake inhibitors, tricyclic antidepressants (such as clomipramine), as well as drugs containing tryptophan (including those of plant origin).

The holder of the registration certificate
PROMOMED RUS LLC, Russian Federation
Address: 13 Mira Avenue, building 1, office 13, Moscow, 129090
Manufacturer
JSC Biochemist, Russian Federation
Legal address: 430030, Republic of Mordovia, Saransk, Vasenko St.,
D. 15A
The address of the place of production: 430030, Republic of Mordovia, Saransk,
Vasenko St., 15A
Phone: +7 (8342) 38-03-68
Email: biohimic@promomed.pro
Internet address: promomed.pro
The organization that accepts consumer claims
PROMOMED RUS LLC, Russian Federation
Address: 13 Mira Avenue, building 1, office 13, Moscow, 129090
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro

Before using GEPREDA®, if you are pregnant, or assume that you could be pregnant, or are planning pregnancy, you should consult your doctor. During breastfeeding, consult your doctor before using GEPREDA®.
The use of GEPREDA® during pregnancy and lactation is not recommended without medical supervision.

Dizziness and a decrease in blood pressure may occur when using GEPREDA®. If these adverse reactions occur, you should refrain from driving vehicles and mechanisms until they disappear.

Do not store at temperatures above 25 °C. Store in the original packaging (pack) to protect from light.
Keep out of reach of children.

3 years old